Harmony Biosciences Holdings, Inc.
Company Stats
- Market Cap
- $2.3B
- as of Sep 30, 2026
- Enterprise Value
- $1.7B
- Shares Outstanding
- 58.2M
- Free Float
- 74.0%
Income Statement
- Revenue
- $868.5M
- Operating Income
- $208.5M
- Net Income
- $158.7M
- Revenue Growth, 3Y
- 25.6%
- FCF Margin, 3Y Avg
- 36.1%
- FCF Margin, Worst Year
- 30.6%
Cash Flow
- Free Cash Flow
- $347.9M
- FCF Yield
- 15.2%
- Owner FCF Yield
- 13.3%
Balance Sheet
- Cash & Equivalents
- $752.5M
- Total Debt
- $165.0M
- Net Cash
- $587.5M
Returns & Capital
- SBC, 3Y Avg
- $39.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $868.5M | $347.9M | 40.1% |
| FY2024 | $714.7M | $218.7M | 30.6% |
| FY2023 | $582.0M | $219.1M | 37.6% |
| FY2022 | $437.9M | $144.3M | 33.0% |
| FY2021 | $305.4M | $98.3M | 32.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back